<i>Review paper<br>Effects of liraglutide – a GLP-1 receptor agonist – on the cardiovascular system</i>

Zofia Ruprecht; Piotr Małecki

eISSN: 2084-9877
ISSN: 1896-9666

Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review

Current issue Archive About the journal Abstracting and indexing Contact Instructions for authors

3/2011
vol. 6

Send email

Copy url:

abstract:

Review paper
Effects of liraglutide – a GLP-1 receptor agonist – on the cardiovascular system

Zofia Ruprecht

,

Piotr Małecki

Przegląd Kardiodiabetologiczny 2011; 6 (3): 220–224

Online publish date: 2011/10/07

View full text Get citation

Glucagon-like peptide-1 (GLP-1) agonists give the opportunity for multiple clinical intervention in type 2 diabetes patients. Beyond glucose control, use of GLP-1 agonists may cause reduction of cardiovascular risk factors. Experimental studies and clinical trials have shown numerous clinical benefits of GLP-1 and the GLP-1 analogue liraglutide on the cardiovascular system, independent of their glycaemic effect. A more complete view of liraglutide’s cardiovascular effect will be provided based on results from the prospective phase III trial LEADER^TM.

keywords:

Review paperEffects of liraglutide – a GLP-1 receptor agonist – on the cardiovascular system

Zofia Ruprecht , Piotr Małecki

diabetes, GLP-1 agonists, liraglutide, cardiovascular complications

Review paper
Effects of liraglutide – a GLP-1 receptor agonist – on the cardiovascular system

Zofia Ruprecht

,

Piotr Małecki